Free Trial

Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S logo with Medical background
Remove Ads

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 61,100 shares, a decrease of 23.5% from the February 13th total of 79,900 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 300 shares, the short-interest ratio is currently 203.7 days.

Genmab A/S Price Performance

OTCMKTS:GNMSF traded down $0.90 during mid-day trading on Tuesday, hitting $204.08. The company's stock had a trading volume of 223 shares, compared to its average volume of 3,048. The business's fifty day moving average is $210.60 and its two-hundred day moving average is $221.88. The stock has a market cap of $13.48 billion, a price-to-earnings ratio of 11.65 and a beta of 1.08. Genmab A/S has a 1 year low of $186.61 and a 1 year high of $310.56.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $5.70 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

See Also

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

SMCI’s Rally Isn’t Over – Here’s Why It Could Hit $100!
7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads